Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with Type 1 Diabetes mellitus.~* Participants treated with multiple daily injections using basal insulin analog once daily and rapid acting insulin analogs for at least one year.~* HbA1c greater than or equal to (\>=) 7 percent (%) (53 millimoles per mole \[mmol/mol\]) and less than or equal to (\<=) 10% (86 mmol/mol) at screening.~Exclusion criteria:~* Participants not on stable dose of basal insulin analog.~* Participants having received Toujeo or Tresiba as basal insulin within 30 days prior to screening.~* Participants not having used the same insulins (both basal and rapid) within 30 days prior to screening.~* Participants having received basal insulin dose \>= 0.6 units per kilogram body weight within 30 days prior to screening.~* Participants having received any glucose lowering drugs (including any premixed insulins, human regular insulin as mealtime insulins, any others injectable or oral), other than basal and rapid insulin analogs, within 3 months prior to screening.~* End stage renal disease or on renal replacement treatment.~* Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.~* Body weight change \>=5 kilogram within 3 months prior to screening.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Toujeo (Type: EXPERIMENTAL): Toujeo (Insulin Glargine, 300 U/ml) subcutaneous (SC) injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.
- Tresiba (Type: ACTIVE_COMPARATOR): Tresiba (Insulin Degludec, 100U/ml) SC injection, once daily in the morning before breakfast for 12 weeks on top of rapid acting insulin analog.

Based on this trial design, predict the completion outcome and termination type (if applicable).